The paraxanthine:caffeine ratio in serum or in saliva as a measure of CYP1A2 activity: When should the sample be obtained?

Pharmacogenetics

Volumn 9, Issue 3, 1999, Pages 409-412

  Spigset, Olav ^a,b   Hägg, Staffan ^a   Söderström, Emma ^a   Dahlqvist, Rune ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Caffeine; CYP1A2; Paraxanthine; Saliva

Indexed keywords

CAFFEINE; CYTOCHROME P450 ISOENZYME; PARAXANTHINE;

ADULT; ARTICLE; BREATH ANALYSIS; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG SALIVA LEVEL; ENZYME ACTIVITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TIME;

ADULT; AREA UNDER CURVE; CAFFEINE; CYTOCHROME P-450 CYP1A2; HUMANS; MALE; SALIVA; SPECIMEN HANDLING; THEOPHYLLINE;

EID: 0032764856     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Campbell ME, Spielberg SP, Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 1987: 42:157-165.
2. Fuhr U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics 1994; 4:109-116.
3. Jeppesen U, Loft S, Poulsen HE, Brosen K. A fluvoxamine-caffeine interaction study. Pharmacogenetics 1996; 6:213-222.
4. Kalow W, Tang B-K. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 1993; 53:503-514.
5. Khanna NN, Bada HS, Somani SM. Use of salivary concentrations in the prediction of serum caffeine and theophylline concentrations in premature infants. J Paediatr 1980; 96:494-499.
6. 2 breath tests as monitors of the cytochrome P450 dependent mixed function monooxygenase system. In: MacLeod SM, Okey AB, Spielberg SP, eds. Developmental pharmacology. New York: Alan R Liss; 1983. pp. 119-145.
7. Notarianni LJ, Oliver SE, Dobrocky P, Bennett PN, Silverman BW. Caffeine as a metabolic probe: a comparison of the metabolic ratios used to assess CYP1A2 activity. Br J Clin Pharmacol 1995; 39:65-69.
8. Schweikl H, Taylor JA. Kitareewan S, Linko P, Nagorney D, Goldstein JA. Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics 1993; 3:239-249.
9. Soto J, Sacristan JA, Alsar MJ. Cerebrospinal fluid concentrations of caffeine following oral drug administration: correlation with salivary and plasma concentrations. Ther Drug Monit 1994; 16:108-110.
10. Spigset O, Granberg K, Hägg S, Söderström E, Dahlqvist R. Nonlinear fluvoxamine disposition. Br J Clin Pharmacol 1998; 45:257-263.
11. Tang B-K, Zhou Y, Kadar D, Kalow W. Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements. Pharmacogenetics 1994; 4:117-124.